Peptide News Digest

#Ale1

2 stories

Industry · View digest

BioMarin Pharmaceutical (NASDAQ: BMRN) Disclosed Wednesday August 26, 2026 Additional Detail on the Previously-Announced Alesta Therapeutics Acquisition (Definitive Agreement Announced August 21): The Transaction Value Is $275 Million and Alesta's Lead Asset ALE1 Is an Oral Hypophosphatasia (HPP) Therapy That Would Challenge the Currently-Approved AstraZeneca / Alexion Enzyme Replacement Strensiq (Asfotase Alfa, a Recombinant Tissue-Nonspecific Alkaline Phosphatase-Fc Fusion Protein Administered as Subcutaneous Injection) With a Smaller-Molecule Oral Format That Could Expand Access to Adult HPP Patients Where the Injectable Enzyme Replacement Has Been Less-Broadly Reimbursed; The Acquisition Continues BioMarin's Rare-Disease Portfolio Expansion Following the Amicus Integration Alongside Voxzogo (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia)

BioMarin Pharmaceutical (NASDAQ: BMRN) disclosed Wednesday August 26, 2026 additional detail on the previously-announced Alesta Therapeutics acquisition (definitive agreement announced August 21). Transaction value: $275 million. Alesta's lead asset ALE1: an oral hypophosphatasia (HPP) therapy in clinical development. Hypophosphatasia is a rare inherited metabolic disease caused by loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme required for bone mineralization and other biological processes; without adequate TNSALP activity, patients develop rickets, osteomalacia, seizures (in the severe perinatal form), and other complications. Commercial context: the currently-approved treatment is AstraZeneca / Alexion's Strensiq (asfotase alfa), a recombinant TNSALP-Fc fusion protein administered as three-times-weekly subcutaneous injection at a list price of approximately $1.5-2.0 million per adult patient per year. ALE1 would compete as a smaller-molecule oral format that could expand access to adult HPP patients where the injectable enzyme replacement has been less-broadly reimbursed by payers due to cost and administration burden concerns. The acquisition continues BioMarin's rare-disease portfolio expansion following the Amicus Therapeutics integration earlier in 2026 (which added GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease) alongside Voxzogo (vosoritide, C-type natriuretic peptide analog for achondroplasia, on track for $1+ billion annual sales in 2026) and the broader enzyme-replacement franchise.

Industry · View digest

BioMarin Pharmaceutical (NASDAQ: BMRN) Announced Friday August 21, 2026 a Definitive Agreement to Acquire Dutch Biotech Alesta Therapeutics to Gain Alesta's Lead Clinical-Stage Asset ALE1, Adding to BioMarin's Rare-Disease Portfolio Alongside VOXZOGO (Vosoritide, C-Type Natriuretic Peptide Analog Administered as Daily Subcutaneous Injection for Achondroplasia and BioMarin's First $1+ Billion Blockbuster Franchise), the Newly-Integrated Amicus Therapeutics Assets (GALAFOLD Migalastat for Fabry Disease, POMBILITI + OPFOLDA Cipaglucosidase Alfa + Miglustat for Late-Onset Pompe Disease), and the Broader Enzyme-Replacement Franchise; The Alesta Acquisition Continues BioMarin's Pattern of Rare-Disease Portfolio Expansion Following the Amicus Integration Completed Earlier in 2026

BioMarin Pharmaceutical (NASDAQ: BMRN) announced Friday August 21, 2026 a definitive agreement to acquire Dutch biotech Alesta Therapeutics to gain Alesta's lead clinical-stage asset ALE1. Financial terms of the transaction were not publicly disclosed. Alesta's ALE1 program is in clinical development; the specific mechanism and indication have not been fully disclosed in initial press coverage, and additional details are expected in the deal filing documents. The acquisition adds to BioMarin's rare-disease portfolio alongside VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as daily subcutaneous injection for achondroplasia in pediatric patients; delivered Q2 2026 revenue of $253 million +14% YoY and is on track for $1+ billion annual sales as BioMarin's first blockbuster franchise), the newly-integrated Amicus Therapeutics assets (GALAFOLD migalastat oral chaperone for Fabry disease, POMBILITI + OPFOLDA cipaglucosidase alfa plus miglustat for late-onset Pompe disease), and the broader enzyme-replacement franchise (VIMIZIM, Naglazyme, Aldurazyme, Palynziq). The Alesta acquisition continues BioMarin's pattern of rare-disease portfolio expansion following the Amicus integration completed earlier in 2026 that added roughly $220 million in expected non-GAAP cost synergies by 2028 and non-GAAP diluted EPS accretion beginning 2027. BioMarin's strategy of building a diversified rare-disease commercial franchise across peptide analogs (Voxzogo), oral small-molecule chaperones (GALAFOLD), enzyme replacements (Palynziq, VIMIZIM, Naglazyme, Aldurazyme), and now Alesta's ALE1 program continues to differentiate the company from single-franchise rare-disease competitors.